Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $41.44.

Several equities research analysts have recently commented on ARWR shares. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley restated a "buy" rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th.

Arrowhead Pharmaceuticals Trading Down 0.1 %

Shares of ARWR stock traded down $0.02 during trading hours on Monday, hitting $13.33. 236,684 shares of the company were exchanged, compared to its average volume of 1,439,388. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The company has a 50 day simple moving average of $14.72 and a two-hundred day simple moving average of $18.43. The firm has a market cap of $1.83 billion, a P/E ratio of -2.58 and a beta of 0.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total value of $406,042.54. Following the completion of the transaction, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at $40,502,093.85. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 275,880 shares of company stock worth $4,034,037. Company insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. New York State Teachers Retirement System lifted its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the first quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock worth $1,890,000 after buying an additional 9,593 shares in the last quarter. KBC Group NV boosted its stake in Arrowhead Pharmaceuticals by 40.8% during the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after buying an additional 2,132 shares during the period. Wealth Effects LLC boosted its stake in Arrowhead Pharmaceuticals by 9.4% during the first quarter. Wealth Effects LLC now owns 170,550 shares of the biotechnology company's stock valued at $2,173,000 after buying an additional 14,675 shares during the period. State of Alaska Department of Revenue grew its position in Arrowhead Pharmaceuticals by 393.4% during the first quarter. State of Alaska Department of Revenue now owns 69,870 shares of the biotechnology company's stock worth $890,000 after buying an additional 55,708 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 31.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock valued at $627,000 after acquiring an additional 11,879 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.